BioStem Technologies (OTCMKTS:BSEM) Upgraded at HC Wainwright

HC Wainwright upgraded shares of BioStem Technologies (OTCMKTS:BSEM) to a strong-buy rating in a report released on Wednesday morning, Marketbeat.com reports.

Separately, Zacks Research raised BioStem Technologies to a “hold” rating in a report on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $9.00.

BioStem Technologies Stock Up 9.5%

BSEM stock opened at $4.50 on Wednesday. The firm has a market cap of $76.41 million, a PE ratio of -10.61 and a beta of 0.09. The business has a 50 day moving average of $4.92 and a 200-day moving average of $4.85. BioStem Technologies has a 12-month low of $3.09 and a 12-month high of $15.45.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.